Palisade Bio

Palisade Bio President & Chief Medical Officer Dr. Mitch Jones highlights the design of the ASCENTRA-UC Phase 2 study evaluating PALI-2108 for ulcerative colitis. Building on Phase 1 findings, the study aims to assess the potential clinical benefits of PALI-2108. $PALI #IBD

Palisade Bio CEO JD Finley highlights the significance of dosing the first patient in the ASCENTRA-UC Phase 2 study. This milestone marks an important step in advancing PALI-2108 as a potential oral treatment for ulcerative colitis. $PALI #Biotech #IBD

Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis bit.ly/4dXWZfC $PALI #UlcerativeColitis #Crohnsdisease #IBD #GIHealth

Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026 bit.ly/480y5Zc $PALI #UlcerativeColitis #Crohnsdisease #IBD #GIHealth

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026 bit.ly/4dAswUE $PALI #UlcerativeColitis #Crohnsdisease #IBD #GIHealth

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026 bit.ly/3TszDaQ $PALI #UlcerativeColitis #Crohnsdisease #IBD #GIHealth

Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance bit.ly/4AsKL83 $PALI #UlcerativeColitis #Crohnsdisease #IBD #GIHealth

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD bit.ly/4xEMEMm $PALI #UlcerativeColitis #Crohnsdisease #IBD #GIHealth

Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum bit.ly/4rrrboP $PALI #UlcerativeColitis #Crohnsdisease #IBD #GIHealth

#InCaseYouMissedIt Our CEO, J.D. Finley and CMO, Mitchell L. Jones, joined The BioHub Podcast by Avetix for a conversation on the progress of PALI-2108 and what lies ahead as we advance toward our Phase 2 ASCENTRA-UC study. Listen here: bit.ly/4h5DgfJ $PALI

Palisade Bio to Participate in Upcoming Investor Conferences bit.ly/4zY1xfm $PALI #UlcerativeColitis #Crohnsdisease #IBD #GIHealth

We were featured on the The BioHub Podcast by Avetix! It was a great opportunity to discuss the progress of PALI-2108 and what we believe it could mean for the future of ulcerative colitis treatment. Listen here: bit.ly/4h5DgfJ $PALI

“The second quarter marked a decisive transition for Palisade Bio as we completed the regulatory and operational work required to advance PALI-2108 into Phase 2 development,” said JD Finley, CEO of Palisade Bio. Read more: bit.ly/4gnvhua $PALI

Palisade Bio reported financial results for Q2 2026 and provided a business update. The Company completed key regulatory and operational activities supporting the planned commencement of the Phase 2 ASCENTRA-UC trial of PALI-2108 in the 2H 2026. bit.ly/4gnvhua $PALI

Attending the Leerink Partners Therapeutics Forum? Palisade's management team will be available for one-on-one investor meetings. For details: bit.ly/4ydWy99 $PALI

JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer of Palisade Bio, will participate in the Leerink Partners Therapeutics Forum, taking place July 14-15, 2026, in Boston, Massachusetts. For details: bit.ly/4ydWy99 $PALI

In parallel with ASCENTRA-UC, Palisade Bio expects to submit an IND application for ASCENTRA-CD in the second half of 2026, highlighting PALI-2108's broad applicability across #IBD indications. For more:: bit.ly/3QwuRaV $PALI #CrohnsDisease #UlcerativeColitis

ASCENTRA-UC is expected to enroll ~204 patients with moderately to severely active #UlcerativeColitis across North America and Europe. First patient enrollment anticipated in 2H 2026; primary efficacy results expected in 2H 2027. Learn more: bit.ly/3QwuRaV $PALI

Mitch Jones, M.D., Ph.D., $PALI President and Chief Medical Officer, comments on the significance of the FDA clearance of an IND application for PALI-2108, marking a major development milestone enabling initiation of a global Ph. 2 ASCENTRA-UC study in UC. bit.ly/3QwuRaV

Palisade Bio today announced FDA clearance of its IND application for PALI-2108, enabling initiation of the global Phase 2 ASCENTRA-UC clinical trial in patients with moderately to severely active #UlcerativeColitis. For details: bit.ly/3QwuRaV $PALI